Lumexa Imaging amends credit agreement with $823 million term loan and $250 million revolver
Subsidiaries of Lumexa Imaging Holdings, Inc. amended their existing credit agreement on June 30, 2026, providing a secured term loan of approximately $823 million and a secured $250 million revolving credit line. The filing describes new restrictive covenants, a leverage test that applies if revolver usage exceeds 40%, and guarantees and collateral pledged by most subsidiaries, which shareholders should weigh as added debt and lender constraints.
Key points
- Replacement term loan of approximately $823 million matures in December 2032, priced at SOFR plus 2.50% or Prime plus 1.50%.
- Revolving credit facility of $250 million matures in December 2030, with pricing at SOFR plus 2.50% or Prime plus 1.50%, subject to reduction on certain leverage ratios.
- If revolver exposure exceeds 40% of the facility at quarter-end, the consolidated net leverage ratio must not exceed 7.50 to 1.
- Barclays Bank PLC is administrative agent; the loans are guaranteed and secured by substantially all wholly-owned subsidiaries' assets, subject to exceptions.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.